Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Eisai Stories

2013-04-11 08:29:51

Newly Created Position to Strengthen Clinical Research WOODCLIFF LAKE, N.J., April 11, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems. In this role, Dr. Kramer will be responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels...

2013-03-26 20:22:33

WOODCLIFF LAKE, N.J., March 26, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ACIPHEX(®) Sprinkle(TM) Delayed-Release Capsules 5mg and 10mg for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks. "We are proud to offer a new treatment option for young children who suffer from GERD," said Lonnel Coats, president and CEO of Eisai Inc. "Eisai is committed to keeping the...

2013-03-22 08:24:59

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice of Issuance from the U.S. Patent and Trademark Office (USPTO) for its patent application entitled "ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088. The USPTO granted claims covering the novel small molecule...

2013-03-05 04:21:08

PARSIPPANY, N.J., March 5, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE/Euronext: DSM KON), today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs. Alexander Wessels, President and CEO of DSM Pharmaceutical Products,...

2013-02-21 08:31:07

WOODCLIFF LAKE, NJ. and MONTREAL, Quebec, Feb. 21, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE: VRX)(TSX: VRX) announced today that Valeant has acquired U.S. rights for Targretin(®) (bexarotene) capsules and Targretin(®) (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones. (Photo:...

2013-02-14 08:28:58

WOODCLIFF LAKE, N.J., Feb. 14, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug lenvatinib (E7080) for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The Orphan Drug Act (ODA) allows FDA to grant orphan status to a drug which has the potential for the treatment,...

2013-02-04 08:26:38

EXTON, Pa., Feb. 4, 2013 /PRNewswire/ -- Morphotek(®) Inc., a subsidiary of Eisai Inc., announced today that its recently opened 60,000-square-foot pilot plant for the production of biological-based therapeutics to support early-stage clinical trials has been designated the 2013 Facility of the Year in the Sustainability category in a competition sponsored by the International Society for Pharmaceutical Engineering (ISPE), INTERPHEX, and Pharmaceutical Processing magazine. The...

2013-01-10 20:21:52

EXTON, Pa., Jan. 10, 2013 /PRNewswire/ -- Morphotek(®) Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse. The study found that farletuzumab in combination with carboplatin and a taxane did not meet the study's primary endpoint of progression-free survival...

2013-01-11 02:20:01

Tokyo, Jan 11, 2013 - (JCN Newswire) - Eisai Co., Ltd. announced today the preliminary results of its global Phase III study (Study FAR 131, MORAb-003-004) of farletuzumab (MORAb-003), an investigational compound under development at its U.S. subsidiary, Morphotek, Inc., in patients with platinum-sensitive epithelial ovarian cancer in first relapse.The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative study of 1,100 patients with...

2013-01-07 08:30:20

CAMBRIDGE, Mass., Jan. 7, 2013 /PRNewswire/ -- Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, Eisai Co., Ltd. (ESALY) and Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a collaboration to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The collaboration's goal is to identify lymphoma patients with non-wild type EZH2, including the Y641 mutation. As...